查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924726

PLA血管支架市場按產品類型、直徑、長度、材質等級、滅菌方法、應用和最終用戶分類－2026-2032年全球預測

PLA Vascular Scaffold Market by Product Type, Diameter, Length, Material Grade, Sterilization Method, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年 PLA 血管支架市值為 1.6302 億美元，預計到 2026 年將成長至 1.9593 億美元，複合年成長率為 18.23%，到 2032 年將達到 5.2668 億美元。

關鍵市場統計數據
基準年 2025 1.6302億美元
預計年份：2026年 1.9593億美元
預測年份 2032 5.2668億美元
複合年成長率 (%) 18.23%

權威的介紹闡述了聚乳酸血管支架如何整合材料科學、手術操作和臨床路徑，從而改善血管癒合效果。

聚乳酸（PLA）血管支架代表了聚合物科學、介入性心臟病學技術和不斷發展的臨床治療路徑的融合，旨在恢復血管通暢性並最大限度地減少長期植入負擔。隨著可吸收支架技術的成熟，研究重點已從概念驗證轉向材料配方、機械設計和滅菌通訊協定的改進，這些因素共同影響支架的輸送性、徑向強度和生物吸收特性。本文將PLA支架置於更廣泛的目標框架下進行探討，即透過提供臨時機械支撐，在血管充分癒合後溶解，從而改善患者的治療效果。

全面概述將重塑PLA血管支架未來發展和應用的技術、臨床和監管轉折點

血管支架領域正經歷著變革性的轉變，這主要得益於技術、臨床和監管方面的重大突破。聚合物化學和複合材料配方的進步使得支架的分解速率更加可預測，機械性能得到提升，進而影響支架的結構和手術操作。影像技術和手術全期策略的發展也正在重塑人們對支架性能的預期，使得支架的成功與否不僅取決於手術的急性期指標，還取決於中期血管重塑情況。

分析2025年美國關稅調整對醫療設備製造商和醫療保健系統的供應鏈、籌資策略和採購優先事項的影響

2025年美國關稅政策引入了新的成本和供應鏈考量因素，將對醫療設備的採購和生產策略產生重大影響。進口關稅和跨境規制度的調整迫使製造商及其供應商重新評估關鍵聚合物原料、精密組件和最終組裝的位置。為此，許多機構正在加快雙源採購計劃並建立庫存緩衝，以減輕關稅相關不確定性對手術可用性的影響。

詳細的細分分析表明，臨床適應症、設備設計、尺寸、材料等級、最終用戶環境和滅菌方法選擇如何決定產品策略。

細分分析揭示了臨床應用、器械架構、醫療環境、尺寸規格、材料等級和滅菌方法選擇如何相互作用，從而決定性能預期和應用路徑。從應用角度來看，冠狀動脈疾病（如心肌梗塞、穩定型心絞痛和不穩定型心絞痛）對徑向強度、急性回縮阻力和短期輸送性能的要求各不相同，而外周邊動脈疾病（如嚴重肢體缺血和間歇性跛行）則需要更長的支架長度和不同的機械順應性。這些臨床情況決定了不同的設計優先順序和手術方案規劃。

區域趨勢和市場進入策略考量表明，不同的法規環境、臨床和供應鏈環境將如何影響PLA支架的應用。

區域趨勢將對聚乳酸血管支架的臨床應用模式、監管方式和供應鏈設計產生重大影響。在美洲，手術量、完善的介入醫學基礎設施以及支付主導的證據要求，使得臨床獲益和真實世界安全性的論證在器械應用討論中佔據優先地位。歐洲、中東和非洲正在經歷轉型，法規環境和臨床實踐模式各不相同。各國報銷模式和醫院能力的差異，要求制定區域性的證據方案和客製化的商業性策略。

競爭洞察：研發、製造、臨床證據和區域供應鏈的整合能力為何決定領導潛力

PLA血管支架領域的主要企業正在調整研發藍圖、生產投資和臨床證據項目，以滿足性能、安全性和法規遵循的全面要求。成熟的醫療設備製造商利用其手術範圍和上市後監測能力進行切實可行的臨床評估，並將臨床醫生的回饋融入迭代設計流程中。同時，敏捷的創新者和專業Start-Ups則專注於改進材料配方、支架幾何形狀和輸送性能，以在特定病變亞組中實現產品性能的差異化。

針對產品設計、製造韌性、臨床證據和相關人員參與等方面的實用策略建議，旨在推動PLA支架的永續應用。

行業領導者可以透過使產品設計與實際臨床和營運情況相符，加速臨床應用和商業性成功。首先，他們優先考慮兼顧可預測吸收性和機械完整性的材料策略，並在必要時投資於複雜的PLA共混物，以實現客製化的分解特性。其次，他們設計的產品組合充分考慮了終端用戶的多樣性，特別是針對門診手術中心、公立和私立醫院以及專科心血管診所等不同需求，提供相應的配置，從而直接滿足採購和庫存管理要求。

透明的混合方法調查方法，結合臨床醫師訪談、技術評估和二手證據綜合，提供可操作的設備見解。

本研究結合了對介入臨床醫生、材料科學家、製造專家、採購經理和監管專家的訪談，以及對同行評審文獻、器械註冊數據和手術指南的二次分析，以期對聚乳酸（PLA）血管支架形成多方面的理解。初步的定性研究揭示了與輸送性、手術流程、滅菌相容性和術後追蹤相關的實際挑戰。技術諮詢則闡明了材料性能和製造的限制。

一項權威的綜合分析，重點闡述了決定聚乳酸血管支架長期成功的相互依存的臨床、技術和操作因素。

聚乳酸（PLA）血管支架在臨時機械支撐和生物相容性可吸收材料的交叉領域佔據著獨特且極具前景的地位。這項技術的潛力不僅取決於聚合物科學和器械幾何結構，還取決於諸如滅菌方法、尺寸選擇以及最終用戶整合新手術流程的能力等實際因素。在冠狀動脈和周邊血管適應症方面，能否成功取決於能否將支架性能與臨床需求、供應鏈實際情況和監管要求相匹配。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的PLA血管支架市場

  • 球囊擴張型支架
  • 自膨脹支架

9. 依直徑分類的PLA血管支架市場

  • 3～5mm
  • 大於5毫米
  • 小於 3 毫米

10. 按長度分類的PLA血管支架市場

  • 10～20mm
  • 超過20毫米
  • 小於10毫米

第11章 依材質等級分類的PLA血管支架市場

  • 複合PLA
    • PLA-PCL共混物
    • PLA-PLLA共混物
  • 標準PLA

12. 依滅菌方法分類的PLA血管支架市場

  • 電子束
  • 環氧乙烷
  • 伽瑪射線照射

第13章 按應用分類的PLA血管支架市場

  • 冠狀動脈疾病
    • 心肌梗塞
    • 穩定性心絞痛
    • 不穩定型心絞痛
  • 周邊動脈疾病
    • 嚴重肢體缺血
    • 間歇性跛行

第14章 依最終用戶分類的PLA血管支架市場

  • 門診手術中心
  • 醫院
    • 私立醫院
    • 公立醫院
  • 專科診所
    • 循環系統診所
    • 血管診所

15. 按地區分類的PLA血管支架市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 按組別分類的PLA血管支架市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 按國家分類的PLA血管支架市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

18. 美國聚乳酸血管支架市場

第19章 中國PLA血管支架市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Amaranth Medical, Inc.
  • Arterial Remodeling Technologies SAS
  • B. Braun Melsungen AG
  • Biosensors International Group, Ltd.
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • CR Bard, Inc.
  • Elixir Medical Corporation
  • Gunze Limited
  • Kyoto Medical Planning Co., Ltd.
  • Lincotek Medical SpA
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • OrbusNeich Medical Company Limited
  • QualiMed Innovative Medizinprodukte GmbH
  • REVA Medical, Inc.
  • Sahajanand Medical Technologies Private Limited
  • Shanghai Bio-heart Biological Technology Co., Ltd.
  • Xenogenics Corporation
Product Code: MRR-7A380DA7C458

The PLA Vascular Scaffold Market was valued at USD 163.02 million in 2025 and is projected to grow to USD 195.93 million in 2026, with a CAGR of 18.23%, reaching USD 526.68 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 163.02 million
Estimated Year [2026] USD 195.93 million
Forecast Year [2032] USD 526.68 million
CAGR (%) 18.23%

An authoritative introduction explaining how polylactic acid vascular scaffolds integrate material science, procedural practice, and clinical pathways to improve vessel healing outcomes

Polylactic acid (PLA) vascular scaffolds represent a convergence of polymer science, interventional cardiology techniques, and evolving clinical care pathways aimed at restoring vessel patency while minimizing long-term implant burden. As resorbable scaffold technology matures, attention has shifted from proof-of-concept toward refining material formulations, mechanical designs, and sterilization protocols that collectively influence deliverability, radial strength, and in vivo resorption profiles. This introduction frames PLA scaffolds within the broader objective of improving patient outcomes by offering temporary mechanical support that dissolves once vascular healing is sufficiently achieved.

Clinical teams and device developers are navigating trade-offs between scaffold durability during the acute healing window and predictable degradation thereafter. Concurrently, the interventional landscape is adapting through optimized imaging, adjunctive pharmacotherapy, and procedural workflows tailored to bioresorbable devices. Regulators and reimbursement stakeholders are likewise seeking robust evidence linking scaffold properties to durable clinical benefit and manageable safety profiles. Taken together, these dynamics position PLA vascular scaffolds as a technology class requiring cross-disciplinary alignment among materials scientists, clinicians, manufacturing experts, and health systems to translate potential into practical, reproducible care innovations.

A comprehensive overview of the technological, clinical, and regulatory inflection points reshaping the future development and adoption of PLA vascular scaffolds

The landscape for vascular scaffolds is experiencing transformative shifts driven by technological, clinical, and regulatory inflection points. Advances in polymer chemistry and composite formulations have enabled more predictable degradation kinetics and enhanced mechanical performance, which in turn have influenced device architecture and procedural adoption. Developments in imaging modalities and periprocedural strategies are also reshaping expectations for scaffold performance, creating an environment where device success is measured both by acute procedural metrics and by medium-term vessel remodeling.

Clinicians are increasingly selective about device choice, favoring scaffold concepts that demonstrate consistent deliverability and low complication rates across diverse lesion subsets. Simultaneously, manufacturing innovations such as precision laser cutting, optimized braid geometries, and controlled crystallinity are enabling thinner-strut designs and more uniform radial force profiles without compromising resorption behavior. Regulatory pathways are evolving to accommodate device-specific evidence frameworks, while payers and health systems emphasize procedures that lower long-term device burden and follow-up resource utilization. As a result, the industry is moving from speculative experimentation toward pragmatic, evidence-aligned product development and commercialization strategies.

Analysis of how the 2025 United States tariff adjustments altered supply chains, sourcing strategies, and procurement priorities for medical device manufacturers and health systems

United States tariff policy enacted in 2025 introduced new cost and supply chain considerations that materially affect device sourcing and production strategies. Import duties and adjustments to cross-border compliance regimes have prompted manufacturers and their supply partners to reassess where critical polymer feedstocks, precision components, and final assembly are located. In response, many organizations are accelerating dual-sourcing plans and increasing inventory buffers to mitigate the impact of tariff-related uncertainties on procedural availability.

These trade shifts have also triggered strategic reassessment among device developers considering localized manufacturing or contractual arrangements that internalize more of the value chain. While clinical safety and device performance remain paramount, procurement teams are now evaluating total landed cost, lead time variability, and supplier resilience as core attributes when selecting scaffold providers. Importantly, ongoing dialogue with regulatory and customs authorities is helping firms streamline compliance processes and reduce time-to-clinic for devices subject to cross-border movement. The net effect is a stronger emphasis on supply chain agility and geopolitical risk management in the commercialization playbook for PLA scaffolds.

A nuanced segmentation synthesis showing how clinical indications, device architecture, dimensions, material grade, end user settings, and sterilization choice determine product strategy

Segmentation analysis reveals how clinical applications, device architectures, care settings, dimensional specifications, material grades, and sterilization choices intersect to define performance expectations and adoption pathways. When viewed through the lens of application, distinctions emerge between coronary artery disease use cases-where myocardial infarction, stable angina, and unstable angina pose differing demands on radial strength, acute recoil resistance, and short-term deliverability-and peripheral artery disease indications such as critical limb ischemia and intermittent claudication that require longer scaffolds and varied mechanical compliance. These clinical states drive divergent design priorities and procedural planning.

Product type segmentation further refines insight by contrasting balloon expandable scaffolds with self expandable designs. Within balloon expandable platforms, thick strut and thin strut approaches trade off radial support versus vessel interaction, whereas self expandable options differentiated by braided mesh or laser-cut architectures offer alternative profiles of flexibility and chronic outward force. End user segmentation emphasizes how ambulatory surgery centers, hospitals, and specialty clinics-each with their own facility capabilities-shape device selection; ambulatory surgery centers divided into dedicated centers and satellite clinics, hospitals split between private and public institutions, and specialty clinics differentiated as cardiology versus vascular centers. Dimensional criteria such as diameters categorized as 3 to 5 mm, greater than 5 mm, and less than 3 mm and lengths segmented into 10 to 20 mm, greater than 20 mm, and less than 10 mm are core determinants of procedural planning and inventory management. Material grade segmentation that separates composite PLA and standard PLA, with composite blends such as PLA/PCL and PLA/PLLA, informs degradation kinetics and mechanical profile decisions. Finally, sterilization method choices among electron beam, ethylene oxide, and gamma radiation have downstream implications for packaging, shelf life, and regulatory filings. Taken together, this layered segmentation framework provides a nuanced map for prioritizing product portfolios and aligning clinical evidence generation across distinct use cases.

Regional dynamics and strategic considerations for market entry demonstrating how differing regulatory, clinical, and supply chain environments shape PLA scaffold adoption

Regional dynamics exert a pronounced influence on clinical adoption patterns, regulatory approaches, and supply chain design for PLA vascular scaffolds. In the Americas, procedural volumes, established interventional infrastructures, and payer-driven evidence expectations create an environment where demonstration of clinical benefit and real-world safety are prioritized in device adoption conversations. Transitioning from this context, Europe, Middle East & Africa present a heterogeneous regulatory tapestry and diverse clinical practice patterns, where country-level reimbursement models and varied hospital capabilities necessitate localized evidence packages and tailored commercial approaches.

Moving to Asia-Pacific, rapid investment in interventional capacity, rising incidence of atherosclerotic disease in aging populations, and strong local manufacturing capabilities are shaping both demand and competitive dynamics. Across regions, differences in sterilization infrastructure, procurement frameworks, and preferred device attributes-such as diameter and length distributions aligned to regional lesion profiles-underscore the need for adaptable product configurations and flexible distribution models. Strategic market entry therefore benefits from a calibrated approach that integrates clinical partnerships, regulatory intelligence, and supply chain localization to meet region-specific clinical and operational requirements.

Insights into the competitive landscape showing why integrated capabilities in R&D, manufacturing, clinical evidence, and localized supply chains determine leadership potential

Leading organizations active in the PLA vascular scaffold space are aligning R&D roadmaps, manufacturing investments, and clinical evidence programs to address the composite requirements of performance, safety, and regulatory compliance. Established medical device manufacturers are leveraging their procedural reach and post-market surveillance capabilities to conduct pragmatic clinical evaluations and integrate clinician feedback into iterative design cycles. Concurrently, nimble innovators and specialized startups are concentrating on material blends, strut geometries, and deliverability enhancements that can differentiate product performance in targeted lesion subsets.

Strategic partnerships between designers, contract manufacturers, and clinical research organizations are playing a pivotal role in accelerating device maturation while controlling capital intensity. Supply chain partners focused on polymer feedstock, precision machining, and sterilization capacity are also critical, particularly as firms consider options to localize production to reduce tariff exposure and lead-time variability. Competitive dynamics favor those companies that can demonstrate reproducible manufacturing quality, robust clinical outcomes across key indications, and a clear regulatory pathway, while also offering practical support for adoption such as training programs and procedural guidance. Investors and executive teams should evaluate prospective partners on the basis of integrated capabilities spanning design, evidence generation, quality systems, and scalable manufacturing.

Actionable strategic recommendations for product design, manufacturing resilience, clinical evidence, and stakeholder engagement to drive durable adoption of PLA scaffolds

Industry leaders can accelerate clinical adoption and commercial success by aligning product design with pragmatic clinical and operational realities. First, prioritize material strategies that balance predictable resorption with mechanical integrity, investing in composite PLA blends where appropriate to achieve tailored degradation profiles. Second, design device portfolios that account for end user variability-offering configurations suitable for ambulatory surgery centers, private and public hospitals, and specialized cardiology and vascular clinics-so that procurement and inventory management requirements are directly addressed.

Third, develop manufacturing and sourcing plans that reduce exposure to tariff-induced volatility through nearshoring, dual sourcing, or strategic inventory buffering, while simultaneously investing in quality systems that support regulatory submissions across jurisdictions. Fourth, pair clinical evidence generation with hands-on training and procedural support to shorten learning curves and demonstrate real-world performance across coronary and peripheral indications. Finally, engage early with regulatory and payer stakeholders to clarify evidence expectations and reimbursement criteria. Collectively, these actions will help organizations position their PLA scaffold offerings for sustainable clinical integration and commercial resilience.

A transparent mixed-methods research methodology combining clinician interviews, technical assessments, and secondary evidence synthesis to deliver actionable device insights

This research synthesizes primary interviews with interventional clinicians, materials scientists, manufacturing specialists, procurement leaders, and regulatory experts, combined with secondary analysis of peer-reviewed literature, device registries, and procedural guidelines to build a multidimensional view of PLA vascular scaffolds. Primary qualitative engagements were structured to surface practical considerations around deliverability, procedural workflows, sterilization compatibility, and post-implant follow-up, while technical consultations clarified material behavior and manufacturing constraints.

Secondary sources were evaluated for methodological rigor, clinical relevance, and recency, with emphasis placed on randomized trials, registry data, and consensus statements from professional societies. Data synthesis followed a triangulation approach to reconcile clinician insights, engineering performance data, and regulatory precedent. The research team applied scenario analysis to explore implications of supply chain shifts and regional regulatory differences, and supplemented findings with procedural case vignettes that illustrate real-world device selection and handling. Wherever applicable, limitations and evidence gaps were documented to inform recommended next steps for developers and health system decision-makers.

A conclusive synthesis highlighting the interdependent clinical, technical, and operational factors that will determine the long-term success of PLA vascular scaffolds

PLA vascular scaffolds occupy a distinct and promising niche at the intersection of temporary mechanical support and biologically compatible resorption. The technology's potential depends not only on polymer science and device geometry but also on practical considerations such as sterilization method, dimensional options, and the capacity of end users to integrate new procedural techniques. Across coronary and peripheral indications, success will be determined by the ability to align scaffold properties with clinical needs, supply chain realities, and regulatory expectations.

Looking ahead, organizations that invest in composite material strategies, rigorous clinical evidence programs, and resilient manufacturing footprints are best positioned to convert technical promise into reproducible clinical value. Collaboration across the clinical, manufacturing, and commercial domains will be essential to realize the full potential of PLA scaffolds. Strategic focus on training, localized support, and transparent post-market surveillance will accelerate clinician confidence and patient access, thereby ensuring the technology fulfills its intended role in contemporary vascular care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. PLA Vascular Scaffold Market, by Product Type

  • 8.1. Balloon Expandable Scaffold
  • 8.2. Self Expandable Scaffold

9. PLA Vascular Scaffold Market, by Diameter

  • 9.1. 3 To 5 Mm
  • 9.2. Greater Than 5 Mm
  • 9.3. Less Than 3 Mm

10. PLA Vascular Scaffold Market, by Length

  • 10.1. 10 To 20 Mm
  • 10.2. Greater Than 20 Mm
  • 10.3. Less Than 10 Mm

11. PLA Vascular Scaffold Market, by Material Grade

  • 11.1. Composite Pla
    • 11.1.1. Pla Pcl Blend
    • 11.1.2. Pla Plla Blend
  • 11.2. Standard Pla

12. PLA Vascular Scaffold Market, by Sterilization Method

  • 12.1. Electron Beam
  • 12.2. Ethylene Oxide
  • 12.3. Gamma Radiation

13. PLA Vascular Scaffold Market, by Application

  • 13.1. Coronary Artery Disease
    • 13.1.1. Myocardial Infarction
    • 13.1.2. Stable Angina
    • 13.1.3. Unstable Angina
  • 13.2. Peripheral Artery Disease
    • 13.2.1. Critical Limb Ischemia
    • 13.2.2. Intermittent Claudication

14. PLA Vascular Scaffold Market, by End User

  • 14.1. Ambulatory Surgery Centers
  • 14.2. Hospitals
    • 14.2.1. Private Hospitals
    • 14.2.2. Public Hospitals
  • 14.3. Specialty Clinics
    • 14.3.1. Cardiology Clinics
    • 14.3.2. Vascular Clinics

15. PLA Vascular Scaffold Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. PLA Vascular Scaffold Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. PLA Vascular Scaffold Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States PLA Vascular Scaffold Market

19. China PLA Vascular Scaffold Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abbott Laboratories
  • 20.6. Amaranth Medical, Inc.
  • 20.7. Arterial Remodeling Technologies SAS
  • 20.8. B. Braun Melsungen AG
  • 20.9. Biosensors International Group, Ltd.
  • 20.10. BIOTRONIK SE & Co. KG
  • 20.11. Boston Scientific Corporation
  • 20.12. C. R. Bard, Inc.
  • 20.13. Elixir Medical Corporation
  • 20.14. Gunze Limited
  • 20.15. Kyoto Medical Planning Co., Ltd.
  • 20.16. Lincotek Medical S.p.A.
  • 20.17. Meril Life Sciences Pvt. Ltd.
  • 20.18. MicroPort Scientific Corporation
  • 20.19. OrbusNeich Medical Company Limited
  • 20.20. QualiMed Innovative Medizinprodukte GmbH
  • 20.21. REVA Medical, Inc.
  • 20.22. Sahajanand Medical Technologies Private Limited
  • 20.23. Shanghai Bio-heart Biological Technology Co., Ltd.
  • 20.24. Xenogenics Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PLA VASCULAR SCAFFOLD MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PLA VASCULAR SCAFFOLD MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES PLA VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA PLA VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY BALLOON EXPANDABLE SCAFFOLD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY BALLOON EXPANDABLE SCAFFOLD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY BALLOON EXPANDABLE SCAFFOLD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY SELF EXPANDABLE SCAFFOLD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY SELF EXPANDABLE SCAFFOLD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY SELF EXPANDABLE SCAFFOLD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY 3 TO 5 MM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY 3 TO 5 MM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY 3 TO 5 MM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN 5 MM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN 5 MM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN 5 MM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY 10 TO 20 MM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY 10 TO 20 MM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY 10 TO 20 MM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN 20 MM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN 20 MM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN 20 MM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 10 MM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 10 MM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 10 MM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PLA PCL BLEND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PLA PCL BLEND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PLA PCL BLEND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PLA PLLA BLEND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PLA PLLA BLEND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PLA PLLA BLEND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY STANDARD PLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY STANDARD PLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY STANDARD PLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY ELECTRON BEAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY ELECTRON BEAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY ELECTRON BEAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY ETHYLENE OXIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY ETHYLENE OXIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY ETHYLENE OXIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY GAMMA RADIATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY GAMMA RADIATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY GAMMA RADIATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY UNSTABLE ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY UNSTABLE ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY CARDIOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY CARDIOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY CARDIOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY VASCULAR CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY VASCULAR CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY VASCULAR CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS PLA VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE PLA VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST PLA VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC PLA VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN PLA VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC PLA VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GCC PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 223. GCC PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 224. GCC PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 225. GCC PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 226. GCC PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 227. GCC PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. GCC PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 229. GCC PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GCC PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 232. GCC PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION PLA VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS PLA VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 259. G7 PLA VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. G7 PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 262. G7 PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 263. G7 PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 264. G7 PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 265. G7 PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 266. G7 PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. G7 PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 268. G7 PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 269. G7 PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. G7 PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 271. G7 PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 272. NATO PLA VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. NATO PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. NATO PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 275. NATO PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 276. NATO PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 277. NATO PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 278. NATO PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 279. NATO PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. NATO PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 281. NATO PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 282. NATO PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. NATO PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 284. NATO PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL PLA VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES PLA VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA PLA VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA PLA VASCULAR SCAFFOLD MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA PLA VASCULAR SCAFFOLD MARKET SIZE, BY DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA PLA VASCULAR SCAFFOLD MARKET SIZE, BY LENGTH, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA PLA VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL GRADE, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA PLA VASCULAR SCAFFOLD MARKET SIZE, BY COMPOSITE PLA, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA PLA VASCULAR SCAFFOLD MARKET SIZE, BY STERILIZATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA PLA VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA PLA VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA PLA VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA PLA VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA PLA VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA PLA VASCULAR SCAFFOLD MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)